Taysha Gene Therapies (NASDAQ: TSHA) reported Q2 EPS of ($0.38), $0.07 worse than the analyst estimate of ($0.31). Revenue for the quarter came in at $2.4 million versus the consensus estimate of $2.1 million.

For earnings history and earnings-related data on Taysha Gene Therapies (TSHA) click here.